F M Thibault1, E Hernandez, D R Vidal, M Girardet, J-D Cavallo. 1. Centre de Recherches du Service de Santé des Armées Emile Pardé, Département de Biologie des Agents Transmissibles, F-38702 La Tronche, France. fthibault@crssa.net
Abstract
OBJECTIVES: Fifty isolates of Burkholderia pseudomallei and 15 isolates of Burkholderia mallei were tested for their susceptibilities to 35 antimicrobial agents, including agents not previously tested against these bacteria. METHODS: MICs were determined by agar dilution in Mueller-Hinton medium. RESULTS: Among the antibiotics tested, lower MICs were obtained with imipenem, ceftazidime, piperacillin, piperacillin/tazobactam, doxycycline and minocycline. Fluoroquinolones and aminoglycosides had poor activities. A single clinical isolate of B. pseudomallei was resistant to ceftazidime, co-amoxiclav and doxycycline but remained susceptible to imipenem. CONCLUSIONS: Although B. mallei MICs are often lower, the overall results underline the importance of resistance in both species. The susceptibilities measured are consistent with the current recommendations for the treatment of B. pseudomallei and B. mallei infections.
OBJECTIVES: Fifty isolates of Burkholderia pseudomallei and 15 isolates of Burkholderia mallei were tested for their susceptibilities to 35 antimicrobial agents, including agents not previously tested against these bacteria. METHODS: MICs were determined by agar dilution in Mueller-Hinton medium. RESULTS: Among the antibiotics tested, lower MICs were obtained with imipenem, ceftazidime, piperacillin, piperacillin/tazobactam, doxycycline and minocycline. Fluoroquinolones and aminoglycosides had poor activities. A single clinical isolate of B. pseudomallei was resistant to ceftazidime, co-amoxiclav and doxycycline but remained susceptible to imipenem. CONCLUSIONS: Although B. mallei MICs are often lower, the overall results underline the importance of resistance in both species. The susceptibilities measured are consistent with the current recommendations for the treatment of B. pseudomallei and B. mallei infections.
Authors: Shawn M Zimmerman; Jeremy S Dyke; Tomislav P Jelesijevic; Frank Michel; Eric R Lafontaine; Robert J Hogan Journal: Infect Immun Date: 2017-07-19 Impact factor: 3.441
Authors: Crystal H Johnson; Brianna L Skinner; Sharon M Dietz; David Blaney; Robyn M Engel; George W Lathrop; Alex R Hoffmaster; Jay E Gee; Mindy G Elrod; Nathaniel Powell; Henry Walke Journal: Comp Med Date: 2013 Impact factor: 0.982
Authors: Liliana Losada; Catherine M Ronning; David DeShazer; Donald Woods; Natalie Fedorova; H Stanley Kim; Svetlana A Shabalina; Talima R Pearson; Lauren Brinkac; Patrick Tan; Tannistha Nandi; Jonathan Crabtree; Jonathan Badger; Steve Beckstrom-Sternberg; Muhammad Saqib; Steven E Schutzer; Paul Keim; William C Nierman Journal: Genome Biol Evol Date: 2010-01-22 Impact factor: 3.416